摘要
转化医学促进了分子生物学等基础医学发展,改变了医学模式。其目的是将医学的基础研究成果快速有效的转化为用于临床的技术和药物,为医学知识服务临床铺平道路。随着肿瘤分子生物学的研究进展,越来越多的分子生物标志物被发现并用于肺癌的诊断、治疗、预后和疗效监测。本文将肺癌分子标志物的研究进展和在转化方面的应用进行综述。
The translational medicine has improved the development of basic medicine such as molecular biology and has changed the medical model.The aim of translational medicine is to translate the basic research achievement of medical biology into technologies and drugs for application quickly and effectively.With the research progress of molecular biology of lung cancer,more molecular biomarkers have been found and used for tumor diagnosis,treatment,prognosis and curative effect surveillance.The research and application of lung cancer molecular markers are summarized as follows.
作者
崔国辉
胡海
Cui Guohui;Hu Hai(Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,Guangdong,China)
出处
《生物医学转化》
2020年第1期79-85,共7页
Biomedical transformation
基金
国家自然科学基金(面上项目:81672738,重点项目:81730077)。
关键词
肺癌
分子标志物
转化医学
Lung cancer
Biomarker
Translational medicine